Abstract: A chemical reaction system is disclosed for use in a device for delivering a therapeutic fluid comprising a liquid base and a polymeric acid. A reaction rate of the chemical reaction system is capable of being adjusted by adjusting at least one of surface area-to-volume ratio, acid concentration, and cross-linking of the polymeric acid.

Abstract: An object of the present invention is to provide a highly effective method for treatment/remission of cancer, and prevention of recurrence/metastasis of cancer at low cost and with few side effects. A composition containing a urinary alkalinization agent, for use in treatment or remission of cancer, or prevention of recurrence or metastasis of cancer.

Abstract: Intravesical drug delivery devices that include a device body, a number of solid drug tablets, and a retention frame. The device body includes a drug reservoir lumen and a retention frame lumen. The drug tablets is positioned in the drug reservoir lumen, and the retention frame is positioned in the retention frame lumen.

Abstract: Extended release pyridostigmine dosage forms, suitable for maintaining stable plasma concentrations with reduced or minimized initial burst release/dose dumping of pyridostigmine, are provided. The dosage forms include matrix tablets, gastroretentive tablets, and pellets, the latter being suitable for dosing in capsules, tablets, and sachets, as well as for sprinkling on foodstuffs. The disclosure also provides methods for improving patient compliance by administering once-a-day extended release pyridostigmine bromide dosage forms that provide a superior controlled drug release.

Abstract: A chemical blowing agent for foaming a thermoplastic polymer, for example PVC plastisol or a polymer resin in an extrusion process, said chemical blowing agent comprising a functionalized particulate bicarbonate containing at least one polyoxyalkylene additive, preferably excluding an exothermic blowing agent. The polyoxyalkylene additive may be selected from the group consisting of polyoxyalkylenes, any derivative thereof, salts thereof, and any combinations thereof. The particulate bicarbonate may be preferably functionalized by spray-coating, extrusion or co-grinding with at least one polyoxyalkylene additive. The functionalized particulate bicarbonate may comprise 50 wt % to less than 100 wt % of the bicarbonate component, and 0.02-50 wt % of the additive. The functionalized particulate bicarbonate may further comprise 0.1-5 wt % silica. A foamable polymer composition comprising such chemical blowing agent.

Abstract: The present disclosure is directed to floating gastroretentive dosage forms with prolonged gastric residence time. The disclosure also provides rapidly expanding sustained release or combined immediate release and sustained release formulations comprising drugs that require targeted release in the proximal gastrointestinal tract for maximum therapeutic benefit. The rapidly expanding floating gastroretentive dosage forms comprise a permeable elastic membrane providing desired characteristics for drug release and mechanical strength to maintain tablet integrity.

Abstract: There is disclosed a dry fertilizer comprising citric acid and potassium carbonate or potassium bicarbonate. The dry fertilizer may be one of a tablet, powder, meal and pellet. The dry fertilizer may include one of plant nutrients, soil nutrients, carbonates, bicarbonates, acids, oils, microorganisms, biostimulants, enzymes, hormones, fertilizers, lubricants, and binding agents. The dry fertilizer may be packaged.

Abstract: Extended release pyridostigmine dosage forms, suitable for maintaining stable plasma concentrations with reduced or minimized initial burst release/dose dumping of pyridostigmine, are provided. The dosage forms include matrix tablets, gastroretentive tablets, and pellets, the latter being suitable for dosing in capsules, tablets, and sachets, as well as for sprinkling on foodstuffs. The disclosure also provides methods for improving patient compliance by administering once-a-day extended release pyridostigmine bromide dosage forms that provide a superior controlled drug release.

Abstract: An effervescent foot bath which employs an acid in combination with a carbonated base to produces a effervescing effect in a closed foot tub. The reaction has been designed to function externally to soften and begin the process of removing dry, rough peeling skin from the feet.

Abstract: Formulations and methods of manufacturing formulations for use in colonic evacuation are disclosed herein, in an embodiment, a solid dosage formulation includes an intra-granular fraction intermingled with an extra-granular fraction, wherein the intra-granular fraction includes granules comprising at least one osmotic evacuant agent, at least one antacid, and a first pharmaceutically acceptable excipient component, and wherein the extra-granular fraction includes one or more organic acids, a non-metallic lubricating element, and a second pharmaceutically acceptable excipient component.

Abstract: The present invention relates to a composite particle comprising: at least one hydrophilic core particle; and a plurality of hydrophobic particles, wherein the surface of the hydrophilic core particle is substantially discontinuously covered by the hydrophobic particles. The novel composite particle according to the present invention can have surface active properties sufficient to prepare stable Pickering emulsions, and can maintain the surface active properties over a long period of time. The present invention also relates to a method for preparing the above composite particle.

Abstract: The present disclosure is directed to floating gastroretentive dosage forms with prolonged gastric residence time. The disclosure also provides rapidly expanding sustained release or combined immediate release and sustained release formulations comprising drugs that require targeted release in the proximal gastrointestinal tract for maximum therapeutic benefit. The rapidly expanding floating gastroretentive dosage forms comprise a permeable elastic membrane providing desired characteristics for drug release and mechanical strength to maintain tablet integrity.

Abstract: The invention encompasses compositions and methods for effectively treating and/or preventing the development and/or progression of osteoarthritis and rheumatoid arthritis and for promoting overall joint health. This is accomplished by totally addressing the key multiple biochemical processes and mechanisms that lead to such disorders. The invention includes compositions comprising a combination of natural agents that safely and effectively suppress, regulate or interfere with the various biochemical processes and mechanisms that increase the risk for or lead to the development and/or progression of OA and RA.

Abstract: An effervescent tablet that exhibits rapid disintegration is disclosed. The effervescent tablet includes an effervescent agent that includes an acid and a base, a crystalline sugar binder selected from the group consisting of crystalline dextrose, crystalline sucrose, crystalline fructose, and combinations thereof, the crystalline sugar binder being essentially free of excipients, a sweetener that includes at least one of Stevia and Monk fruit, a flavor agent that includes a gum Arabic carrier, and optionally a lubricant derived from rice hulls (e.g., a multi-component integral lubricant).

Abstract: Extended release pyridostigmine dosage forms, suitable for maintaining stable plasma concentrations with reduced or minimized initial burst release/dose dumping of pyridostigmine, are provided. The dosage forms include matrix tablets, gastroretentive tablets, and pellets, the latter being suitable for dosing in capsules, tablets, and sachets, as well as for sprinkling on foodstuffs. The disclosure also provides methods for improving patient compliance by administering once-a-day extended release pyridostigmine bromide dosage forms that provide a superior controlled drug release.

Abstract: The present invention relates to a compressed solid composition for MRI comprising a physiologically acceptable manganese (II) compound, its preparation and use for preparing an oral solution.

Abstract: Compositions and methods to avoid the gag reflex to enable swallowing of pills, by applying an edible coating to the pill that generates bubbles, so that the bubbles prevent direct contact of the pill with the back of the mouth, thereby avoiding the gag reflex. Preferably the coating generates bubbles from an acid-base reaction, from compressed bubbles entrapped in hard candy, or from any other manner for creating fizzing, effervescent or popping confectionery or other food products. Optionally the coating can have a strong taste, such as by being sour, to distract away from the gag reflex. Optionally, a time release envelope is provided to delay bubbling or to block atmospheric humidity.

Abstract: An orthopaedic implant includes an implant body having a first surface, a second surface opposite the first surface, and a cavity formed therein that extends through the first surface and the second surface. The implant body has a third surface with at least one first opening formed therethrough to the cavity. The at least one first opening includes an outer portion having an outer diameter and an inner portion having an inner diameter. The implant includes a load bearing member including a porous material held within the cavity. The outer portion of the at least one first opening is configured to couple to a tool for receiving, from the tool, a material agent, and the inner portion of the at least one first opening is configured to couple to a plug for preventing the material agent from exiting the porous material via the at least one first opening.

Abstract: The invention includes compositions and methods for improving exercise performance or improving recovery of muscle tissue after exercise performance. One method includes administering a composition of a plant-derived nitrate and a cocoa-derived product daily and before exercise. The synergistic combination of nitrate and cocoa polyphenols acts to improve recovery from a strenuous exercise bout.

Abstract: An effervescent chewable dosage form that comprises a pH neutralization agent, an acid, and an effervescent agent. The chewable dosage form can also further comprise simethicone, a sweetener, and a lubricant. The pH neutralization agent can be calcium carbonate, the acid can be citric acid and the effervescent agent can be sodium bicarbonate.

Abstract: Disclosed are methods, compositions and kits for whitening teeth and promoting better oral hygiene. A one-step protocol is disclosed in which concentrated hydrogen peroxide is delivered into the oral cavity by aerosol spray, without burning, discomfort or damage to the soft tissues of the mouth. A two-step protocol is also disclosed in which an effervescent powder formulation is included as a post-treatment following the aerosol spray. In some embodiment, the powder formulation can be used alone to promote remineralization, reduce plaque, reduce bacterial count and generally enhance oral hygiene.

Abstract: There are provided pharmaceutical compositions comprising a compound of Formula (I) as defined herein and an amount of an alkaline effervescent agent that is sufficient to provide satisfactory in vitro dissolution; and further comprising one or more pharmaceutically acceptable ingredients; and to processes for obtaining them.

Abstract: The present invention relates to a capsule composition of raloxifene comprising multiparticulates comprising a) a core comprising raloxifene, and b) a taste-masking coating present in amount of from about 0.5% to about 50% w/w based on the core weight.

Abstract: The invention provides coated particles with a taste-masked drug substance. The particles comprise a core with the agglomerated active ingredient and a coating comprising a triglyceride and a surfactant. The particles exhibit rapid drug release and a stable release profile. Moreover, the invention provides a hot-melt coating method for manufacturing such particles, and pharmaceutical compositions comprising the particles. The method allows the coating of core particles at moderate temperatures, thereby preventing the degradation of the thermolabile active ingredient.

Abstract: The present invention relates to a particulate material and a solid dosage form notably tablets comprising a regularly shaped calcium-containing compound such as a calcium salt as a therapeutically and/or prophylactically active substance and a pharmaceutically acceptable sugar alcohol such as, e.g., sorbitol and/or isomalt that has a micro structure as evidenced by SEM. The invention also relates to a process for the preparation of the particulate material and solid dosage form. The process involves agglomeration of the calcium-containing compound and the pharmaceutically acceptable sugar alcohol by means of roller compaction. The particulate material obtained by roller compaction is suitable for use in the further processing of the particulate material into e.g. tablets such as chewing tablets.

Abstract: Disclosed is a water-repellent film 102 including a substrate 100, and a water-repellent organic material provided on the substrate 100, in which a plurality of regions having different concentrations of the water-repellent organic material are formed, and each of the regions having different concentrations continuously exists in a film thickness direction from a boundary surface with respect to the substrate to a surface of the water-repellent film. Preferably, in the regions having different concentrations, a region having a relatively higher concentration 102a is formed into the shape of a column, and a region having a relatively lower concentration 102b than that of the columnar region exists around the columnar region.

Abstract: The present invention provides an oral film-form base which has a rapid dissolution profile in the mouth and sufficient film strength, and gives an improved taking property by foaming in the mouth. The oral film-form base includes an edible polymer soluble both in water and in an organic solvent having a solubility parameter of 9.7 or higher, a foaming agent, and an auxiliary foaming agent, wherein the foaming agent is foamable in the presence of water, and the foaming agent and the auxiliary foaming agent each are insoluble in the organic solvent, have an average particle size of 0.1 to 60 ?m, and are included in particle states.

Abstract: Disclosed herein are water-soluble films and resulting packets including a water-soluble film coated by a powder, wherein the powder includes a mixture of a powdered lubricant and an active agent. Optionally, the active agent may be encapsulated, e.g. microencapsulated, for release of the active agent through mechanisms including, but not limited to, mechanical rupture, melt, ablation, dissolution, diffusion, biodegradation, or pH-controlled release. Active ingredients described include enzymes, oils, flavors, colorants, odor absorbers, fragrances, pesticides, fertilizers, activators, acid catalysts, metal catalysts, ion scavengers, bleaches, bleach components, fabric softeners and combinations thereof. Examples of packet fills include laundry detergents, bleach and laundry additives, fabric care, dishwashing, hard surface cleaning, beauty care, skin care, other personal care, and foodstuffs.

Abstract: There is provided a method for preparing an orally disintegrating tablet (ODT) composition comprising microparticles of one or more taste-masked active pharmaceutical ingredient(s), rapidly-dispersing microgranules, and other optional, pharmaceutically acceptable excipients wherein the ODT disintegrates on contact with saliva in the buccal cavity in about 60 seconds forming a smooth, easy-to-swallow suspension. Furthermore, the microparticles (crystals, granules, beads or pellets containing the active) applied with a taste-masking membrane comprising a combination of water-insoluble and gastrosoluble polymers release not less than about 60% of the dose is in the stomach in about 30 minutes, thus maximizing the probability of achieving bioequivalence to the reference IR product having rapid onset of action (short Tmax). A process for preparing such compositions for oral administration using conventional fluid-bed equipment and rotary tablet press is also disclosed.

Abstract: The present invention relates to complexes of beepollen and clay, as well as to their preparation methods and to their therapeutic uses or as a food supplement, a functional food, in human and animal healthcare.

Abstract: The invention relates to solid medicinal forms containing at least one active ingredient and at least one pharmaceutically compatible, water soluble drying agent which is selected from the group consisting of trimagnesium dicitrate and/or calcium chloride, the solid medicinal form having a drying loss of at most 6% and a relative equilibrium moisture content of 25% or less. The invention also relates to solid medicinal forms containing a moisture-sensitive active ingredient and trimagnesium dicitrate.

Abstract: The present invention provides an oral delivery system for a therapeutic compound that is an acid, a salt of an acid or an unionized compound or a proactive form thereof with pharmacological, physiological or biochemical activity. The present invention particularly provides a swallow formulation comprising a therapeutic compound that is an acid, a salt of an acid or an unionized compound or a proactive form thereof which facilitates the rapid delivery of the therapeutic compound to the circulatory system.

Abstract: A stable effervescent tablet, granule or powder composition free from excipients that may react with an effervescing organic acid component, comprising, an effective amount of a bisphosphonate bone resorption inhibitor, an effervescing organic acid component, an effervescing base component; wherein said composition is free of polyol binders and tableting lubricants; has a loss on drying of 0.25% (m/m) or less; has a complete disintegration time of no more than 180 seconds when placed in 3 to 8 fluid ounces of water at between 5-20° C.; and said bisphosphonate is incorporated as a micronized particle or by spray drying and is completely solubdised in water within 2 minutes without stirring.

Abstract: A composition for the treatment or prevention of a disorder resulting in hair loss comprises a cardiac glycoside as active principal.

Abstract: The present invention relates to an effervescent composition in solid form for use in vaginal applications for the treatment of vaginal infections.

Abstract: An oral dosage form for administration to an animal comprising a biologically utilizable form of calcium and an extended release system that maintains the calcium level in the animal's bloodstream at a substantially beneficial level for a defined period of time.

Abstract: Effervescent pharmaceutical compositions containing a high amount of N-acetylcysteine and a method of treating acetaminophen poisoning with effervescent pharmaceutical compositions containing a high amount of N-acetylcysteine are described.

Abstract: Disclosed herein are water-soluble films and resulting packets including a water-soluble film coated by a powder, wherein the powder includes a mixture of a powdered lubricant and an active agent. Optionally, the active agent may be encapsulated, e.g. microencapsulated, for release of the active agent through mechanisms including, but not limited to, mechanical rupture, melt, ablation, dissolution, diffusion, biodegradation, or pH-controlled release. Active ingredients described include enzymes, oils, flavors, colorants, odor absorbers, fragrances, pesticides, fertilizers, activators, acid catalysts, metal catalysts, ion scavengers, bleaches, bleach components, fabric softeners and combinations thereof. Examples of packet fills include laundry detergents, bleach and laundry additives, fabric care, dishwashing, hard surface cleaning, beauty care, skin care, other personal care, and foodstuffs.

Abstract: The present invention provides immediate release pharmaceutical compositions for oral administration that are resistant to abuse by intake of alcohol.

Abstract: Described herein is the Bruton's tyrosine kinase (Btk) inhibitor 1-((R)-3-(4-amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)piperidin-1-yl)prop-2-en-1-one, including crystalline forms, solvates and pharmaceutically acceptable salts thereof. Also disclosed are pharmaceutical compositions that include the Btk inhibitor, as well as methods of using the Btk inhibitor, alone or in combination with other therapeutic agents, for the treatment of autoimmune diseases or conditions, heteroimmune diseases or conditions, cancer, including lymphoma, and inflammatory diseases or conditions.

Abstract: The invention provides compositions for preventing or treating kidney disease comprising vitamin E, vitamin C, and a carotenoid and methods for preventing and treating kidney disease comprising administering such compositions to an animal susceptible to or suffering from kidney disease. In a preferred embodiment, the composition is admixed with one or more food ingredients to produce a food composition useful for preventing or treating kidney disease.

Abstract: A carbon dioxide source tablet is disclosed including a body comprising carbon dioxide source reactable with liquid to produce carbon dioxide gas. The body includes a top side opposite a bottom side, and one or more peripheral sides extending between the top side and the bottom side. The body also includes at least one channel. Each channel extends along one of the top side and the bottom side. Each channel extends in length from a first channel end to a second channel end. Each first and second channel end is located at one of the peripheral sides. Each channel, between its first and second channel ends, is spaced from the peripheral sides. Each channel provides a frangible line of weakness. At least a portion of each channel extends linearly from the channel's first channel end to the channel's second channel end. A beverage carbonating system is also disclosed.

Abstract: The present invention is related to novel oral compositions comprising an irreversible gastric H+/K+ ATPase proton pump inhibitor (PPI) as a gastric acid secretion inhibitor and one or more small carboxylic acid molecules as parietal cell activators in the gastric lumen. Unexpectedly, the compositions of the present invention are capable of enhancing the anti-acid activity of PPI in the stomach. The present invention further relates to a method of using such compositions to reduce gastric acid secretion in a mammal.

Abstract: Provided is a composition for preventing or treating osteoporosis. The composition contains an ibandronic acid, or a pharmaceutically acceptable salt thereof, or a hydrate thereof, and vitamin D. The composition has uniform medicinal effects by minimizing the differences in physical properties between ibandronic acid, or the pharmaceutically acceptable salt thereof, or the hydrate thereof, and vitamin D.

Abstract: The present invention relates to immediate release pharmaceutical compositions for oral administration that are resistant to abuse by intake of alcohol. In particular, this disclosure provides immediate release pharmaceutical compositions comprising a polyglycol having a molecular weight of from about 900 to about 17,000 daltons, a drug substance, one or more effervescent agents, and, optionally, one or more disintegrants, such that the composition is formulated to be resistant to abuse by intake of alcohol.

Abstract: Effervescent tablets, powders and granules are provided which may be dissolved in water to produce an effervescent rehydrating beverage. The effervescent tablet, powder and granule compositions of the invention deliver electrolytes and carbohydrates at levels that provide hypotonic, isotonic or slightly hypertonic solution when dissolved in water, with acceptable taste.

Abstract: The present invention relates to a process for preparing effervescent dosage forms comprising at least one antibiotic of cephalosporin group. The present invention also relates to effervescent formulations and preparations comprising antibiotics of second generation cephalosporin.

Abstract: The present invention relates to a micro-particle for extending satiety and controlling blood glucose and lipid levels, comprising a core having the protein extract from sweet potato, an active ingredient layer coated on the core, and a protection layer coated over the active ingredient layer as an external layer, wherein the protein extract from sweet potato contains trypsin inhibitor and glycoprotein. The micro-particle comprising a protein extract from sweet potato can effectively extend satiety, control blood glucose and lipid levels and increase metabolism effectively.

Abstract: The present invention relates to a pharmaceutical composition for direct oral administration which is very easy to swallow especially for young children, comprising at least one pharmaceutically active compound. The pharmaceutical composition is present in the form of one or more particles. The particles comprise a core containing the active ingredient which has been provided with one or more coatings. The pharmaceutical composition is preferably administered in combination with a powder and/or granules which, when applied to the tongue, spontaneously generate additional saliva. With the extra saliva, the coated particles form a soft, smooth, but mechanically stable surface perceived as pleasant in the mouth within seconds so that they may be swallowed easily and practically in the right quantity with the extra saliva formed.

Abstract: The present invention includes compositions and methods for reduce the taste of the drug in the drug resin complex. The composition may include one or more drug-resin complexes and a highly compressible, free-flowing pharmaceutical excipient. The resin is present in an amount effective to reduce the taste of the drug in the drug resin complex relative to an otherwise identical pharmaceutical composition without the resin; and wherein the highly compressible, free-flowing pharmaceutical excipient causes release of the drug-resin complex in the mouth.